Drug Approval | June 01, 2024
Moderna receives U.S. FDA approval for RSV Vaccine mRESVIA
mRESVIA is Moderna's second approved product and the only RSV vaccine available in single-dose pre-filled syringes
mRESVIA is Moderna's second approved product and the only RSV vaccine available in single-dose pre-filled syringes
Greg was also central to the planning, design, and construction of this facility
Bluecrux's digital supply chain twin technology, Axon, plays a critical role in Sanofi's digital supply chain transformation.
This marks the first FDA approval of an AI-based brain disorder analysis solution from Korea
Phase I data for tuvusertib, lead asset from the company’s unique portfolio of DDR inhibitors
Establishing Asymchem’s first manufacturing footprint in Europe
Operationally ready by 2029, it will be the Company’s first-ever facility to cover the full manufacturing process for ADCs
Sanofi will leverage this partnership to provide access to proprietary data to develop AI models
Additional data from APPRAISE ATP trial reinforce modular therapy approach
At the recommended Phase 3 dose of 200 mg vepdegestrant in combination with palbociclib, patients achieved a median progression-free survival of 13.9 months
Subscribe To Our Newsletter & Stay Updated
